Sanofi

View All

dupixent-market
Can Dupixent Be A Gamechanger In The Atopic Dermatitis Treatment Landscape?

Dupixent (dupilumab) is a non-immunosuppressive fully human monoclonal antibody that inhibits the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. According to data from Dupixent clinical trials, IL-4 and IL-13 are key drivers of type 2 inflammation, which is a major contributor to Atopic...

Find More

drugs-launched-in-second-half-2021
Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did not cease developing new treatments this year. The US Food and Drug Administration maintained a rapid rate of new drug approvals this year, all while managing the urgent examination of COVID-19 tests, treatments, and vaccines un...

Find More

top-pharma-biotech-companies-by-revenue-share-drugs-therapies-2020-2021-worldwide
Top 7 Pharma Industry Leaders in 2020 By the Numbers

Pharmaceutical companies play a vital part in our lives and in helping us to live healthier lives. The pharmaceutical industry finds, develops, manufactures, and promotes medicines or pharmaceutical drugs for usage as medications that are administered (or self-administered) to patients in order to cure, vaccinate, ...

Find More

insulin-delivery-devices-market-trends-and-key-companies
Cost-effectiveness, Advanced Technology, Rising Demand Pushes the Insulin Delivery Devices Market

Insulin is a hormone secreted by the beta cells of the islets of langerhans in the pancreas. The hormone is responsible for the maintenance of normal blood glucose levels by facilitating cellular glucose uptake and regulating carbohydrate, protein, and lipid metabolism. Inappropriate functioning of insulin due to d...

Find More

COVID-19-Vaccines-Hemophilia-B-uniQure-Gene-Therapy-J-J-Covid-Vaccine-Covaxin
Ocugen-Bharat Biotech’s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal

Ocugen-Bharat Biotech’s Covaxin Shows Efficacy Against B.1.617 Variant With the COVID-19 cases exponentially increasing, there is a worrisome climate all over the world. Physicians, doctors, researchers, the whole healthcare and pharmaceutical industry are at their toes fighting the second wave of the coronaviru...

Find More

recent-pharma-news-and-updates-for-astrazeneca-sanofi-taysha
Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities

Taysha takes charge of a Rare Disease Gene Therapy for $5.5 M  Taysha Gene Therapies announced the acquisition of exclusive global rights to TSHA-120 from a leading patient advocacy group for an upfront payment of USD 5.5 million.  TSHA-120 is an intrathecally dosed AAV9 gene therapy designed to tre...

Find More

pharma-happenings-for-gbt-sanofi-eli-lilly-glooko-solid-biosciences
GBT strikes a deal with Sanofi; Lilly’s IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy

Global Blood Therapeutics strikes a deal with Sanofi for sickle cell disease programs As Global Blood Therapeutics works to bring its sickle cell disease drug, Oxbryta, to younger patients, the company is reinforcing its pipeline with a pair of early-stage programs from Sanofi. In exchange for the global righ...

Find More

recent-pharma-happenings-for-pfizer-sanofi-elevation-oncology
Pfizer succeeds COVID-19 vaccine safety milestone; Sanofi snags speedy review for BTK drug; Autoimmune diseases research updates; Elevation Oncology secures $65 M

Pfizer succeeds COVID-19 vaccine safety milestone Pfizer prepares to file its COVID-19 vaccine for emergency use authorization (EUA) after succeeding a key safety breakthrough. Pfizer now has the median two-month follow-up data needed for securing EUA from the FDA, moving a step closer for bringing its vaccine t...

Find More

pharma happenings for BMS Sanofi GW Pharmaceuticals Kiadis
Bristol Myers’ psoriasis drug; GW Pharmaceuticals eyes US market for Nabiximols; Karyopharm’s Xpovio; Kiadis USD 358M Buyout

Bristol Myers' Experimental Psoriasis drug succeeds in late-stage study defeats rival Amgen's Otezla Bristol Myers' experimental psoriasis drug, deucravacitinib has outmarched Amgen's Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial in patients with moderate to severe plaque psoriasis. Deucravaci...

Find More

pharma news
Sanofi acquires Principia; FDA’s Nod to Roche’s Enspryng; BMS, Dragonfly’s Licensing Deal

New strategy, new outlook: Sanofi takes another step, gains full control over the Principia’s MS treatment  Sanofi has inked a definitive agreement with Principia Biopharma to acquire the company, all of its outstanding shares, and its BTK inhibitors in a deal worth USD 3.68 Billion. The deal is expected t...

Find More